Hypothalamic Obesity in Craniopharyngioma Patients: Disturbed Energy Homeostasis Related to Extent of Hypothalamic Damage and Its Implication for Obesity Intervention
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Hypothalamic obesity (HO) occurs in patients with tumors and lesions in the medial hypothalamic region. Hypothalamic dysfunction can lead to hyperinsulinemia and leptin resistance. This review is focused on HO caused by craniopharyngiomas (CP), which are the most common childhood brain tumors of nonglial origin. Despite excellent overall survival rates, CP patients have substantially reduced quality of life because of significant long-term sequelae, notably severe obesity in about 50% of patients, leading to a high rate of cardiovascular mortality. Recent studies reported that both hyperphagia and decreased energy expenditure can contribute to severe obesity in HO patients. Recognized risk factors for severe obesity include large hypothalamic tumors or lesions affecting several medial and posterior hypothalamic nuclei that impact satiety signaling pathways. Structural damage in these nuclei often lead to hyperphagia, rapid weight gain, central insulin and leptin resistance, decreased sympathetic activity, low energy expenditure, and increased energy storage in adipose tissue. To date, most efforts to treat HO have shown disappointing long-term success rates. However, treatments based on the distinct pathophysiology of disturbed energy homeostasis related to CP may offer options for successful interventions in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“GLP-1 is secreted in response to ingestion of nutrients [149].”
BackgroundEuropean Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Mechanisms linking obesity with cardiovascular disease
Van Gaal, L. F., Mertens, I. L., & De Block, C. E. (2006) · Nature · doi:10.1038/nature05487 · Cited by 2,814 · cited 1×
“Thus, early and effective management of obesity is vital for these patients [48], which are more”
BackgroundCentral nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503 · cited 1×
“The ARC contains two well-studied neuronal populations [64], one expressing proopiomelanocortin, a precursor of α-melanocyte stimulating hormone that inhibits food intake and stimulates energy expenditure; the other co-expressing agouti-related peptide and neuropeptide-Y, which both stimulate food intake and reduce en…”
BackgroundObesity is associated with hypothalamic injury in rodents and humans.
Thaler, J. P., Yi, C.-X., Schur, E. A., Guyenet, S. J., Hwang, B. H., Dietrich, M. O., Zhao, X., Sarruf, D. A., Izgur, V., Maravilla, K. R., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59660 · Cited by 1,857
Milanski, M., Degasperi, G., Coope, A., Morari, J., Denis, R., Cintra, D. E., Tsukumo, D. M. L., Anhe, G., Amaral, M. E., Takahashi, H. K., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2760-08.2009 · Cited by 1,125
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 1×
“Peripheral administration of GLP-1 or GLP1RA reduces blood glucose and energy intake in humans and rodents, and long-term treatment results in loss of body weight [158–175].”
BackgroundThe arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity
El-Haschimi, K., Pierroz, D. D., Hileman, S. M., Bjørbæk, C., & Flier, J. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9842 · Cited by 887
Region-Specific Leptin Resistance within the Hypothalamus of Diet-Induced Obese Mice
Münzberg, H., Flier, J. S., & Bjørbæk, C. (2004) · Endocrinology · doi:10.1210/en.2004-0726 · Cited by 737 · cited 1×
“Leptin activates PVN OXT neurons through a melanocortin-4 receptor (MC4R) dependent mechanism, whereas leptin resistance is associated with downstream impairments in OXT release [70–72].”
BackgroundPosey, K. A., Clegg, D. J., Printz, R. L., Byun, J., Morton, G. J., Vivekanandan-Giri, A., Pennathur, S., Baskin, D. G., Heinecke, J. W., Woods, S. C., et al. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90377.2008 · Cited by 586
GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M. (2014) · Diabetes · doi:10.2337/db14-0849 · Cited by 427 · cited 1×
“By binding to these receptors, GLP-1 functions as a satiety hormone, promoting reduced food intake and meal termination [153–156], as well as modulating activity in appetite- and reward-related brain areas [157].”
BackgroundFlint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384 · cited 1×
“whether GLP1RA treatment also affects energy expenditure and activity in subjects with hypothalamic lesions [176–179].”
BackgroundMinireview: Inflammation and Obesity Pathogenesis: The Hypothalamus Heats Up
Thaler, J. P., & Schwartz, M. W. (2010) · Endocrinology · doi:10.1210/en.2010-0336 · Cited by 313
Müller, H. L., Emser, A., Faldum, A., Bruhnken, G., Etavard-Gorris, N., Gebhardt, U., Oeverink, R., Kolb, R., & Sörensen, N. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031751 · Cited by 287
Neuroinflammation and neurodegeneration in overnutrition-induced diseases
Cai, D. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.11.003 · Cited by 256 · cited 2×
“astrocytosis and astrogliosis, increased cytokine expression, neural dysregulation of the hypothalamus, neurodegeneration, and defective adult neurogenesis [10,111–113].”
BackgroundHarz, K. J., Müller, H. L., Waldeck, E., Pudel, V., & Roth, C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021797 · Cited by 214 · cited 2×
“While many patients report hyperphagia, recent studies have also reported an overall decrease in energy intake in patients with HO compared with controls [27,28].”
BackgroundResultSelf-citationFeatures of the metabolic syndrome after childhood craniopharyngioma
Srinivasan, S., Ogle, G. D., Garnett, S. P., Briody, J. N., Lee, J. W., & Cowell, C. T. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030442 · Cited by 211 · cited 1×
“Patients with CP typically become obese and display more features of the metabolic syndrome compared to matched controls [34,44].”
BackgroundHypothalamic inflammation and energy homeostasis: Resolving the paradox
Thaler, J. P., Choi, S. J., Schwartz, M. W., & Wisse, B. E. (2010) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2009.10.002 · Cited by 144 · cited 1×
“induction of suppressor of cytokine signaling (SOCS-3) [111,114–116].”
BackgroundHamilton, J., Conwell, L., Syme, C., Ahmet, A., Jeffery, A., & Daneman, D. (2011) · International Journal of Pediatric Endocrinology · doi:10.1155/2011/417949 · Cited by 109 · cited 1×
“Another attempt to treat hyperinsulinemia was combined diazoxide-metformin therapy; this was associated with reduced weight gain but significant side effects limited the enthusiasm after the initial pilot study [50].”
BackgroundArch, J. R. S. (2008) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-008-0271-1 · Cited by 96 · cited 1×
“More promising candidates are agents acting further “downstream” such as melanocortin (MC) receptor agonists that stimulate MC and are expressed in hypothalamic nuclei as well as extrahypothalamic and peripheral tissues [133], melanin-concentrating hormone-1 receptor antagonists that antagonize the strong orexigen mel…”
BackgroundSemiquantitative analysis of hypothalamic damage on MRI predicts risk for hypothalamic obesity
Roth, C. L., Eslamy, H., Werny, D., Elfers, C., Shaffer, M. L., Pihoker, C., Ojemann, J., & Dobyns, W. B. (2015) · Obesity · doi:10.1002/oby.21067 · Cited by 96
Self-citationJensterle, M., Kocjan, T., Kravos, N. A., Pfeifer, M., & Janez, A. (2015) · Endocrine Research · doi:10.3109/07435800.2014.966385 · Cited by 86 · cited 1×
“Peripheral administration of GLP-1 or GLP1RA reduces blood glucose and energy intake in humans and rodents, and long-term treatment results in loss of body weight [158–175].”
BackgroundPinelli, N. R., & Hurren, K. M. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q024 · Cited by 59 · cited 1×
“Peripheral administration of GLP-1 or GLP1RA reduces blood glucose and energy intake in humans and rodents, and long-term treatment results in loss of body weight [158–175].”
BackgroundMihály, E., Fekete, C., Légrádi, G., & Lechan, R. M. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03094-8 · Cited by 47 · cited 11×
“Key regions thought to be the principal homeostatic brain areas responsible for regulating body weight are dispersed throughout the hypothalamus with important centers located in anterior (paraventricular nucleus, PVN), middle (arcuate nucleus, ARC, and ventromedial nucleus, VMN) and posterior (dorsomedial nucleus, DM…”
BackgroundInfluentialTriiodothyronine supplementation for hypothalamic obesity
Fernandes, J. K., Klein, M. J., Ater, J. L., Kuttesch, J. F., & Vassilopoulou-Sellin, R. (2002) · Metabolism · doi:10.1053/meta.2002.35591 · Cited by 39
A Novel Rodent Model That Mimics the Metabolic Sequelae of Obese Craniopharyngioma Patients
Roth, C. L., Blevins, J. E., Ralston, M., Elfers, C., Ogimoto, K., Kaiyala, K. J., & Morton, G. J. (2011) · Pediatric Research · doi:10.1203/pdr.0b013e3182083b67 · Cited by 35 · cited 5×
“developed a novel rat model of combined medial hypothalamic lesions (CMHL) to study the pathogenesis of HO and test potential drugs for obesity treatment and prevention [6,41].”
BackgroundInfluentialSelf-citationCardiac risk after craniopharyngioma therapy
Mong, S., Pomeroy, S. L., Cecchin, F., Juraszek, A., & Alexander, M. E. (2008) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2007.11.007 · Cited by 34
van Santen, H. M., Schouten-Meeteren, A. Y., Serlie, M., Meijneke, R. W. H., van Trotsenburg, A. S., Verberne, H., Holleman, F., & Fliers, E. (2015) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2014-0337 · Cited by 32
Norwood, P., Liutkus, J. F., Haber, H., Pintilei, E., Boardman, M. K., & Trautmann, M. E. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.09.007 · Cited by 24 · cited 1×
“Peripheral administration of GLP-1 or GLP1RA reduces blood glucose and energy intake in humans and rodents, and long-term treatment results in loss of body weight [158–175].”
Background
Cited by
Hypothalamic inflammation and obesity: a mechanistic review
Seong, J., Kang, J. Y., Sun, J. S., & Kim, K. W. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01138-9 · Cited by 158
van Iersel, L., Brokke, K. E., Adan, R. A. H., Bulthuis, L. C. M., van den Akker, E. L. T., & van Santen, H. M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00017 · Cited by 146
Roth, C. L., Perez, F. A., Whitlock, K. B., Elfers, C., Yanovski, J. A., Shoemaker, A. H., & Abuzzahab, M. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14224 · Cited by 87
Self-citationDiagnostic criteria for the hypothalamic syndrome in childhood
van Santen, H. M., van Schaik, J., van Roessel, I. M. A. A., Beckhaus, J., Boekhoff, S., & Müller, H. L. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad009 · Cited by 67
Acquired hypothalamic obesity: A clinical overview and update
Roth, C. L., & McCormack, S. E. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15530 · Cited by 42
“Synthetic MC receptor agonists are promising for the treatment of genetic and surgery-induced HO affecting the MC4R pathway 119 as there is clear evidence that central MC signalling is deficient 8,45,46,65,120,121 in individuals with these conditions.”
BackgroundSelf-citation
Metadata
- Authors
- Roth, C.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2015-09-09
- Volume
- 4
- Issue
- 9
- Pages
- 1774-1797
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W2152549483
- Cited by
- 89
- References
- 30
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.